REG - Oncimmune Hldngs PLC - Grant of Options and PDMR notification

Oncimmune HoldingsAnnouncement

01/05/2020 10:35

RNS Number : 6510L
  
Oncimmune Holdings PLC
  
01 May 2020
  
 

 
Oncimmune Holdings plc
("Oncimmune" or the "Company")
 
Grant of Options and PDMR notification
 
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that options to subscribe for an aggregate 546,052 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted to Matthew Luttrell, Chief Commercial Officer, Tariq Sethi, Chief Scientific Officer, and Ron Kirschner, General Counsel & Company Secretary as follows:
 



Name


Position


Number of Share Options Awarded


Exercise Price per Share




Matthew Luttrell


Chief Commercial Officer


223,684


£0.76




Tariq Sethi


Chief Scientific Officer


92,105


£0.76




Ron Kirschner


General Counsel & Company Secretary


230,263


£0.76



 
The Options have been granted under the 2016 Share Option Plan and have an exercise price of £0.76, being the closing price of shares at 30 April 2020.  
 
Other than the grant of the Options, none of Mr Luttrell, Mr Sethi or Mr Kirschner or their respective connected persons have any beneficial interest in the Ordinary Shares of the Company.
 
This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


1)   Matthew Luttrell
2)   Tariq Sethi
3)   Ron Kirschner




2
 


Reason for the notification
 




a)
 


Position/status
 
 


1)   Chief Commercial Officer
2)   Chief Scientific Officer
3)   General Counsel & Company Secretary




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


Oncimmune Holdings plc




b)
 


LEI
 
 


213800HCYIWT6YPI1I02 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of £0.01 each
 














Identification code


ISIN: GB00BYQ94H38














b)
 


Nature of the transaction
 
 


Grant of options




c)
 


Price(s) and volume(s)




























Price(s)


Volume(s)
















1) £0.76


223,684
















2) £0.76


92,105
















3) £0.76


230,263






























d)
 


Aggregated information


















- Aggregated volume


546,052          














- Price


£414,999.52














e)
 


Date of the transaction
 
 


1 May 2020




f)
 


Place of the transaction
 
 


Outside a trading venue



 
For further information:
Oncimmune Holdings plc
Ron Kirschner, General Counsel & Company Secretary
contact@oncimmune.co.uk
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHUPUBPAUPUUBG